Jeffrey S. Albert

Gebundenes Buch

Pharmacologic Schizophrenia

Beschreibung

This book provides a comprehensive resource for neuro drug discovery and molecular targets for schizophrenia, from current therapies to evolving targets. The coverage begins with a discussion of prevalence and etiology, and an introduction to current therapies (which treat only certain, "positive" symptoms), as well as the rise of interest in addressing untreated symptoms. Subsequent sections focus on each major mechanistic hypothesis, beginning with a chapter that serves as an introduction and overview. Within these models, chapters focus on each major pharmacological target and address both the neurobiological and chemical aspects of that target.

Autor

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Produktdetails

• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 494
• Erscheinungstermin: 10. Juli 2012
• Englisch
• Abmessung: 240mm x 161mm x 31mm
• Gewicht: 815g
• ISBN-13: 9780470322826
• ISBN-10: 0470322829
• Artikelnr.: 34743779